SEC Comment Letter for Corbus Pharmaceuticals Holdings, (CRBP) — Mar 13, 2026
Corbus Pharmaceuticals Holdings, Inc.
Date: March 13, 2026 · CIK: 0001595097 · Accession: 0000000000-26-002620
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-294217
Letter
Re: Corbus Pharmaceuticals Holdings, Inc. Registration Statement on Form S-3 Filed March 11, 2026 File No. 333-294217 Dear Yuval Cohen:
March 13, 2026
Yuval Cohen Chief Executive Officer Corbus Pharmaceuticals Holdings, Inc. 500 River Ridge Drive Norwood, MA 02062
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Chris Edwards at 202-551-6761 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Stephen G. Zapf, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> March 13, 2026 Yuval Cohen Chief Executive Officer Corbus Pharmaceuticals Holdings, Inc. 500 River Ridge Drive Norwood, MA 02062 Re: Corbus Pharmaceuticals Holdings, Inc. Registration Statement on Form S-3 Filed March 11, 2026 File No. 333-294217 Dear Yuval Cohen: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at 202-551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Stephen G. Zapf, Esq. </TEXT> </DOCUMENT>